^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Melanoma

    Related cancers:
    15h
    Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=92, Recruiting, Aminex Therapeutics, Inc.
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • fulvestrant • Truqap (capivasertib) • AMXT 1501
    16h
    X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov)
    P1, N=20, Recruiting, Immunolight, LLC | Trial completion date: Mar 2026 --> Mar 2029 | Trial primary completion date: Sep 2025 --> Sep 2028
    Trial completion date • Trial primary completion date
    |
    methoxsalen (X-PACT)
    18h
    Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma (clinicaltrials.gov)
    P1/2, N=100, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Entyvio (vedolizumab)
    23h
    Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma (clinicaltrials.gov)
    P1/2, N=13, Terminated, John Kirkwood | Trial completion date: Dec 2028 --> Feb 2025 | Active, not recruiting --> Terminated; Secura Bio, Inc. discontinued support of the trial.
    Trial completion date • Trial termination
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Opdivo (nivolumab) • Inlyta (axitinib) • Copiktra (duvelisib)
    1d
    Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification (clinicaltrials.gov)
    P=N/A, N=1650, Recruiting, European Organisation for Research and Treatment of Cancer - EORTC | N=1250 --> 1650 | Trial completion date: Dec 2026 --> Jul 2038 | Trial primary completion date: Aug 2026 --> Dec 2027
    Enrollment change • Trial completion date • Trial primary completion date
    1d
    TRIDeNT: Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    BRAF mutation • BRAF V600
    |
    Opdivo (nivolumab) • Mekinist (trametinib) • Tafinlar (dabrafenib) • Mektovi (binimetinib) • Braftovi (encorafenib)
    2d
    Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) (clinicaltrials.gov)
    P2, N=494, Not yet recruiting, Melanoma Institute Australia | Trial completion date: Sep 2037 --> Jan 2038 | Trial primary completion date: Dec 2027 --> Mar 2028
    Trial completion date • Trial primary completion date • IO biomarker
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    2d
    HLA export by melanoma cells decoys cytotoxic T cells to promote immune evasion. (PubMed, Cell)
    These findings suggest that MHC export protects melanoma from the cytotoxic effects of T cells. Our study highlights a novel immune evasion mechanism and proposes a therapeutic avenue to enhance tumor immunity.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    2d
    The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, Mayo Clinic
    New P2 trial
    2d
    Erianin Abrogates Cancerous Vasculogenic Mimicry Through Targeting m5C Methylase NSUN2 in Uveal Melanoma. (PubMed, Invest Ophthalmol Vis Sci)
    Collectively, our data suggest that erianin serves as an inhibitor of vasculogenic mimicry. Our results unveil a novel therapeutic strategy for combating malignant progression by fine-tuning m5C modification with a natural product.
    Journal
    |
    CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • CHAC1 (ChaC Glutathione Specific Gamma-Glutamylcyclotransferase 1) • NOP2 (NOP2 Nucleolar Protein)
    3d
    Continuous electrochemical H2O2 delivery for cancer cell treatment. (PubMed, J Mater Chem B)
    This novel approach of electrochemical H2O2 delivery holds significant potential for enhancing targeted cancer therapies, offering a controllable, precise, and efficient method for inducing tumor cell death while minimizing damage to healthy tissues. These results showcase the remarkable ability of PEDOT electrodes as a reliable electrocatalytic source of on-demand H2O2 in electrochemically-challenging biological environments.
    Journal
    |
    CAT (Catalase)
    3d
    A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body (clinicaltrials.gov)
    P1/2, N=240, Recruiting, Regeneron Pharmaceuticals | N=150 --> 240
    Enrollment change • First-in-human
    |
    Libtayo (cemiplimab-rwlc)